Showing 1271-1280 of 1319 results for "".
- Virtual Scottsdale Headache Symposium Starts Tomorrow!https://practicalneurology.com/news/virtual-scottsdale-headache-symposium-starts-tomorow/2469436/The American Headache Society's educational meeting launches online tomorrow, November 21, 2020, at 9 AM Pacific time and there is still time to register. The virtual meeting will include LIVE sessions updating the audience on core topics in headache including diagnosis, epidemiology, acute a
- Ghrelin Advances to a Phase 2 Trial for Concussion Treatmenthttps://practicalneurology.com/news/ghrelin-advances-to-a-phase-2-trial-for-concussion-treatment/2469406/A phase 2 clinical trial (NCT04558346) of ghrelin (OXE103; Oxeia Biopharmaceuticals, San Diego, CA) for treating concussions has been initiated. The compound being tested is a synthetic form of the end
- FDA Extends Expiration Dating for Diazepam Nasal Sprayhttps://practicalneurology.com/news/fda-extends-expiration-dating-for-diazepam-nasal-spray/2469404/The Food and Drug Administration (FDA) has granted extended expiration dating for diazepam nasal spray (Valtoco; Neurelis, Inc., San Diego, CA). Diazepam was approved by the FDA on January 10, 2020, for the acute treatment of intermittent stereotypic episodes of frequent seizure activity th
- Opicapone Decreases Off Time in Parkinson Diseasehttps://practicalneurology.com/news/opicapone-decreases-off-time-in-parkinson-disease/2469380/Post hoc analyses presented at the Movement Disorder Society's Virtual Congress 2020 September 12-16 showed once-daily opicapone (Ongentys; Neurocrine Biosciences, San Diego, CA) decreased off time’ and increased on time without troublesome dyskinesia in Parkinson disease (PD). Opicapon
- FDA Accepts Supplemental New Drug Application for Pimavanserin for Dementia-Related Psychosis Symptomshttps://practicalneurology.com/news/fda-accepts-supplemental-new-drug-application-for-pimavanserin-for-dementia-related-psychosis-symptoms/2469329/The Food and Drug Administration (FDA) has accepted for filing its supplemental new drug application (sNDA) for pimavanserin (Nuplazid; Acadia Pharmaceuticals, San Diego, CA) for the treatment of hallucinations and delusions associated with dementia-related psychosis (DRP). The sNDA is
- Rare Genetic Mutations Linked to Parkinson Disease Identified in Pilot Studyhttps://practicalneurology.com/news/rare-genetic-mutations-linked-to-parkinson-disease-identified-in-pilot-study/2469313/In the PD GENEration: Mapping the Future of Parkinson's Disease pilot study (NCT04057794), approximately 17% of all participants tested positive for genetic mutations linked to Parkinson
- FDA Grants Orphan Drug Designation for Primary Mitochondrial Myopathies Treatmenthttps://practicalneurology.com/news/fda-grants-orphan-drug-designation-for-primary-mitochondrial-myopathies-treatment/2469310/The Food and Drug Administration (FDA) office of orphan products development has granted orphan drug designation to a peroxisome proliferator-activated receptor (PPAR) delta agonist, (REN001; Reneo Pharmaceuticals, San Diego, CA), for the treatment of primary mitochondrial myopathies (PMM).
- New Indication for Pimavanserin—Dementia Related Psychosis—Submitted to the FDAhttps://practicalneurology.com/news/new-indication-for-pimavanserin-dementia-related-psychosis-submitted-to-the-fda/2469301/A supplemental new drug application (sNDA) for pimavanserin (Nuplazid; Acadia Pharmaseuticals, San Diego, CA) was submitted to the Food and Drug Administration (FDA) for a new indication. Evidence now shows pimavanserin is effective for the treatment of hallucinations and delusions associated wit
- Phase 2 Clinical Trial of LSD for Cluster Headaches Initiatedhttps://practicalneurology.com/news/phase-2-clinical-trial-of-lsd-for-cluster-headaches-initiated/2469288/A phase 2 trial (NCT03781128) for lysergic acid diethylamide (LSD) pulse regimen (Mind Medicine, Basel, Switzerland) for cluster headache treatment started recruiting participants in
- FDA Approves Opicapone as Adjunctive to Levodopa for Parkinson Diseasehttps://practicalneurology.com/news/fda-approves-opicapone-as-adjunctive-to-levodopa-for-parkinson-disease/2469240/The US Food and Drug Administration (FDA) has approved once-daily oral opicapone (Ongentys, Neurocrine Biosciences, San Diego, CA) 25 mg and 50 mg capsules as an add-on treatment to levodopa/carbidopa in individuals with Parkinson disease (PD) experiencing off episodes. Opicapone also increases o